Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Current Assets
All assets expected to be converted to cash or used up within one year.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 26.7% from a year ago
Total current assets stood at $379.78M at the end of Q1 FY2026, up 26.7% from a year earlier and up 8.6% from the prior quarter. Over 3 fiscal years it compounded at +48.8% a year.
Context
- Total current assets amounted to 90.5% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +26.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 349.72M USD
- Year-over-year change
- +73.4%
- 3-year CAGR
- +48.8%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 349.72M | +73.4% |
| FY2024 | 2024-12-31 | 201.67M | +491.2% |
| FY2023 | 2023-12-31 | 34.11M | -67.9% |
| FY2022 | 2022-12-31 | 106.15M | — |
Total Current Assets vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +26.7% is the 4th highest of 8, against a peer median of +22.1%.
- Total current assets amounts to 90.5% of total assets for MAZE, versus a peer median of 81.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $2.62B USD | +15.2% | +48.5% | 80.5% | |
| Sep 2026 | $633.45M USD | +70.7% | -3.5% | 74.7% | |
SEPNSepterna, Inc. | Sep 2026 | $507.35M USD | +3.2% | +134.4% | 81.9% |
BIOABioAge Labs, Inc. | Mar 2026 | $391.86M USD | +20.6% | +117.1% | 98.5% |
| Mar 2026 | $381.87M USD | +22.1% | +35.5% | 75.7% | |
| Mar 2026 | $379.78M USD | +26.7% | +48.8% | 90.5% | |
| Dec 2025 | €243.84M EUR | +118.7% | +31.8% | 98.0% | |
| Mar 2026 | $52.36M USD | +39.9% | +21.5% | 98.6% | |
| Peer median (excluding MAZE) | — | +22.1% | +35.5% | 81.9% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.